Cargando…

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein

Detalles Bibliográficos
Autores principales:	Hinner, Marlon J, Aiba, Rachida-Siham Bel, Wiedenmann, Alexander, Schlosser, Corinna, Allersdorfer, Andrea, Matschiner, Gabriele, Rothe, Christine, Moebius, Ulrich, Kohrt, Holbrook E, Olwill, Shane A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649453/ http://dx.doi.org/10.1186/2051-1426-3-S2-P187

Ejemplares similares

Contributions of Costimulatory Molecule CD137 in Endothelial Cells
por: Yuan, Wei, et al.
Publicado: (2021)

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
por: Weth, R, et al.
Publicado: (2004)

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li, Shi-Yan, et al.
Publicado: (2013)

The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
por: Peper-Gabriel, Janet K., et al.
Publicado: (2022)

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
por: Houot, Roch, et al.
Publicado: (2012)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
por: Vinay, Dass S., et al.
Publicado: (2014)

Predicting CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy
por: Makkouk, Amani, et al.
Publicado: (2015)

A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
por: Geuijen, Cecile, et al.
Publicado: (2021)

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
por: Chu, Dinh-Toi, et al.
Publicado: (2019)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
por: Rajendran, Sakthi, et al.
Publicado: (2019)

The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota
por: Blake, Stephen J., et al.
Publicado: (2021)

Costimulatory pathways in transplantation
por: Pilat, Nina, et al.
Publicado: (2011)

Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway
por: Fenwick, Craig, et al.
Publicado: (2019)

ANNINE-6plus, a voltage-sensitive dye with good solubility, strong membrane binding and high sensitivity
por: Fromherz, Peter, et al.
Publicado: (2007)

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
por: Negri, D. R., et al.
Publicado: (1995)

Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation
por: Kuwahara, Atsushi, et al.
Publicado: (2020)

Neuroimmune semaphorins as costimulatory molecules and beyond
por: Chapoval, Svetlana P.
Publicado: (2018)

Targeting Costimulatory Pathways in Systemic Sclerosis
por: Boleto, Gonçalo, et al.
Publicado: (2018)

Altered expression of costimulatory molecules in dementias
por: Busse, Stefan, et al.
Publicado: (2021)

Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody
por: Schick, Arthur J., et al.
Publicado: (2022)

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2
por: Scheuer, Werner, et al.
Publicado: (2016)

A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023)

Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity
por: Asano, Ryutaro, et al.
Publicado: (2018)

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
por: Feng, Yan, et al.
Publicado: (2022)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
por: Wutti-in, Yupanun, et al.
Publicado: (2022)

Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF
por: Ward, Claire, et al.
Publicado: (2010)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition
por: Yu, Xiaocong, et al.
Publicado: (2016)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
por: Huang, Sijia, et al.
Publicado: (2018)

Prospective Design of Anti‐Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain
por: Kanodia, JS, et al.
Publicado: (2016)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

Expression of costimulatory molecules in the bovine corpus luteum
por: Cannon, Matthew J, et al.
Publicado: (2007)

Targeting Costimulatory Molecules to Improve Antitumor Immunity
por: Capece, Daria, et al.
Publicado: (2012)

γδ T cell costimulatory ligands in antitumor immunity
por: McGraw, Joseph M., et al.
Publicado: (2022)

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody
por: Meng, Weixu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rib8li1btl3uhjg6okcjo006ds